FDA: Lutathera Action Date Set for Late January 2018

Advanced Accelerator Applications S.A. (AAA) has announced that the Food and Drug Administration (FDA), in the United States, has accepted and considered complete the resubmission of the New Drug Application (NDA) for its investigational drug lutetium Lu 177 dotatate (Lutathera).  Lutathera is the brand name for the radiologic used in Peptide Receptor Radionuclide Therapy (PRRT). The FDA has set an action date of Jan 26, 2018. AAA is attempting to obtain U.S.

Treatment combinations for pancreatic neuroendocrine tumors

A new paper has recently been released in Digestion: International Journal of Gastroenterology that reviewed previously reported European trials. These trials specifically aimed at the treatment of advanced pancreatic neuroendocrine tumors outlined several combinations of chemotherapy drugs used to help with progression free survival (PFS). Pancreatic neuroendocrine tumors (PNETS) are still relatively rare in the umbrella of all gastroenteropancreatic tumors (GEP-NETS or just NETS) and certainly amongst pancreatic lesions in general.

Expanded Access to PRRT in the United States

We have exciting news in regards to Peptide Receptor Radionuclide Therapy (PRRT) therapy in the United States. Advanced Accelerator Applications is currently pursuing marketing approval for 177Lu-DOTA0-Tyr3-Octreotate (Lutathera). Considering that Phase III NETTER-1 clinical trial recruitment has been completed, this expanded access therapeutic protocol aims to allow patients suffering from inoperable, somatostatin receptor positive, midgut carcinoid tumors, progressive under somatostatin analogue therapy to access the investigational product, 177Lu-DOTA0-Tyr3-Octreotate (Lutathera), prior to

Felicia Temple: The Voice

It’s not often that we have a reason to discuss reality television shows here on Northwoods NETS, but, we have a notable exception right now. The Voice contestant, Felicia Temple, 28, is also a neuroendocrine tumor patient. An amazing vocalist and songwriter, Ms. Temple was diagnosed with a appendiceal neuroendocrine tumor last year. A registered RN, she underwent surgery and six rounds of chemo before her doctor declared her NED. She

Meet Dr. Thor Halfdanarson at our November 13th Meeting

Join us for our regularly scheduled support group meeting on November 13th and meet Dr. Thor Halfdanarson. This meeting takes place three days after NET Cancer Day and is our last for 2016. Dr. Thor will be giving an overview presentation on neuroendocrine tumors, what’s new and upcoming in treatments and diagnostics, and do a question and answer session with our patient community. Dr. Thor is a trained medical oncologist who